About belite bio inc. - BLTE
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
BLTE At a Glance
Belite Bio, Inc.
12750 High Bluff Drive
San Diego, California 92130
| Phone | 1-858-246-6240 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -77,611,000.00 | |
| Sector | Health Technology | Employees | 41 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BLTE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.167 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -58.187 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
BLTE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,892,951.22 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BLTE Liquidity
| Current Ratio | 50.017 |
| Quick Ratio | 50.017 |
| Cash Ratio | 49.83 |
BLTE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -16.642 |
| Return on Equity | -16.94 |
| Return on Total Capital | -10.067 |
| Return on Invested Capital | -16.932 |
BLTE Capital Structure
| Total Debt to Total Equity | 0.056 |
| Total Debt to Total Capital | 0.056 |
| Total Debt to Total Assets | 0.055 |
| Long-Term Debt to Equity | 0.024 |
| Long-Term Debt to Total Capital | 0.024 |